These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38206118)

  • 1. Obesity and harmful alcohol consumption are predictors for advanced liver disease in the disease management program for type 2 diabetes.
    Michel M; Doll M; Albert N; Morgenstern M; Behr A; Maxeiner S; Labenz C; Galle PR; Schattenberg JM
    United European Gastroenterol J; 2024 Feb; 12(1):11-21. PubMed ID: 38206118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study.
    Abeysekera KWM; Fernandes GS; Hammerton G; Portal AJ; Gordon FH; Heron J; Hickman M
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):295-305. PubMed ID: 31954687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.
    Ajmera V; Cepin S; Tesfai K; Hofflich H; Cadman K; Lopez S; Madamba E; Bettencourt R; Richards L; Behling C; Sirlin CB; Loomba R
    J Hepatol; 2023 Mar; 78(3):471-478. PubMed ID: 36410554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impairment of health-related quality of life among people with type 2 diabetes and advanced liver fibrosis.
    Michel M; Funuyet-Salas J; Doll M; Alqahtani SA; Armandi A; Labenz C; Galle PR; Schattenberg JM
    Sci Rep; 2024 Sep; 14(1):21650. PubMed ID: 39289410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stratification Of LIver Disease (SOLID): protocol for a prospective observational cohort study to determine the optimum biomarker strategies for the detection of advanced liver disease at the primary-secondary care interface.
    McPherson S; Jarvis H; McGonigle J; Bedlington J; Dean J; Hallsworth K; Hanon E; Liddle T; Luvai A; Mansour D; Patel P; Renwick L; Teare D; Tanney C; Anstee Q
    BMJ Open Gastroenterol; 2023 Feb; 10(1):. PubMed ID: 36754448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
    Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study.
    Demir M; Deyneli O; Yılmaz Y
    Turk J Gastroenterol; 2019 Mar; 30(3):266-270. PubMed ID: 30411703
    [TBL] [Abstract][Full Text] [Related]  

  • 8.  High prevalence of undiagnosed liver cirrhosis and advanced fibrosis in type 2 diabetic patients.
    Arab JP; Barrera F; Gallego C; Valderas JP; Uribe S; Tejos C; Serrano C; Serrano C; Huete Á; Liberona J; Labbé P; Quiroga T; Benítez C; Irarrázaval P; Riquelme A; Arrese M
    Ann Hepatol; 2016; 15(5):721-8. PubMed ID: 27493111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross-sectional study using transient elastography.
    Harman DJ; Ryder SD; James MW; Wilkes EA; Card TR; Aithal GP; Guha IN
    Aliment Pharmacol Ther; 2018 Feb; 47(4):504-515. PubMed ID: 29210096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes.
    Ciardullo S; Monti T; Perseghin G
    Diabetes Care; 2021 Feb; 44(2):519-525. PubMed ID: 33303638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modest alcohol intake not associated with significant hepatic steatosis or more severe liver disease among patients with diabetes mellitus.
    Tan EZ; Lai LL; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    J Gastroenterol Hepatol; 2021 Mar; 36(3):751-757. PubMed ID: 32583444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study.
    Alfadda AA; Sherbeeni SM; Alqutub AN; Aldosary AS; Aldaghri NM; Taylor-Robinson SD; Alqahtani SA; Gul R; Almaghamsi AM
    Saudi J Gastroenterol; 2022; 28(6):426-433. PubMed ID: 35645140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneously Screening for Liver Steatosis and Fibrosis in Romanian Type 2 Diabetes Mellitus Patients Using Vibration-Controlled Transient Elastography with Controlled Attenuation Parameter.
    Trifan A; Stratina E; Nastasa R; Rotaru A; Stafie R; Zenovia S; Huiban L; Sfarti C; Cojocariu C; Cuciureanu T; Muzica C; Chiriac S; Girleanu I; Singeap AM; Stanciu C
    Diagnostics (Basel); 2022 Jul; 12(7):. PubMed ID: 35885657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic causes of liver disease among adults living with HIV from low- and middle-income countries: a cross-sectional study.
    Plaisy MK; Minga AK; Wandeler G; Murenzi G; Samala N; Ross J; Lopez A; Mensah E; de Waal R; Kuniholm MH; Diero L; Salvi S; Moreira R; Attia A; Mandiriri A; Shumbusho F; Goodrich S; Rupasinghe D; Alarcon P; Maruri F; Perrazo H; Jaquet A;
    J Int AIDS Soc; 2024 Apr; 27(4):e26238. PubMed ID: 38566493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors associated with nonalcohol fatty liver disease and fibrosis among patients with type 2 diabetes mellitus.
    Zhao H; Song X; Li Z; Wang X
    Medicine (Baltimore); 2018 Sep; 97(37):e12356. PubMed ID: 30212992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany.
    Labenz C; Huber Y; Kalliga E; Nagel M; Ruckes C; Straub BK; Galle PR; Wörns MA; Anstee QM; Schuppan D; Schattenberg JM
    Aliment Pharmacol Ther; 2018 Nov; 48(10):1109-1116. PubMed ID: 30288767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The presence of diabetes impacts liver fibrosis and steatosis by transient elastography in a primary care population.
    Trivedi HD; Suri J; Oh D; Schwartz J; Goyes D; Idriss R; Curry MP; Lai M
    Ann Hepatol; 2021; 24():100336. PubMed ID: 33647502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes.
    Ciardullo S; Perseghin G
    Metabolism; 2021 Aug; 121():154752. PubMed ID: 33716004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study.
    Long MT; Zhang X; Xu H; Liu CT; Corey KE; Chung RT; Loomba R; Benjamin EJ
    Hepatology; 2021 Feb; 73(2):548-559. PubMed ID: 33125745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes.
    Bridi L; Agrawal S; Tesfai K; Madamba E; Bettencourt R; Richards LM; Khera AV; Loomba R; Ajmera V
    Aliment Pharmacol Ther; 2024 Aug; 60(3):369-377. PubMed ID: 38825972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.